The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.

[1]  M. Rousseau,et al.  Increased CRP: An extended biomarker of microvascular risk in men with type2diabetes. , 2019, Journal of diabetes and its complications.

[2]  C. Gobbi,et al.  Marcadores subclínicos de aterosclerosis y factores de riesgo cardiovascular en artritis temprana , 2019, Revista de la Facultad de Ciencias Medicas.

[3]  A. Rossi,et al.  Weight Loss and Hypertension in Obese Subjects , 2019, Nutrients.

[4]  Yusong Zhang,et al.  Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis , 2019, BMC Cancer.

[5]  Haowen Jiang,et al.  Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans , 2019, Cell Death & Disease.

[6]  Kanikkai Raja Aseer,et al.  Dietary polyphenols and their roles in fat browning. , 2019, The Journal of nutritional biochemistry.

[7]  Carrie D. Patnode,et al.  Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[8]  Xiang Liu,et al.  Hepatoprotective effects of berberine on acetaminophen-induced hepatotoxicity in mice. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  Karla I. Galaviz,et al.  Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose , 2018, Diabetes Care.

[10]  S. Latifi,et al.  The Effects of Active Ingredients of Barberry Root (Berberine) on Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients , 2018 .

[11]  Lixian Liu,et al.  The design and synthesis of a novel compound of berberine and baicalein that inhibits the efficacy of lipid accumulation in 3T3-L1 adipocytes. , 2017, Bioorganic & medicinal chemistry.

[12]  H. Lan,et al.  C‐reactive protein and ageing , 2017, Clinical and experimental pharmacology & physiology.

[13]  D. Panagiotakos,et al.  Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel , 2017, Archives of medical science : AMS.

[14]  Lei Zhang,et al.  Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. , 2017, Atherosclerosis.

[15]  W. Pan,et al.  Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels , 2017, Molecular medicine reports.

[16]  H. Zhang,et al.  Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance. , 2016, Life sciences.

[17]  H. Fan,et al.  Berberine Attenuates Inflammation Associated with Delayed-Type Hypersensitivity via Suppressing Th1 Response and Inhibiting Apoptosis , 2016, Inflammation.

[18]  V. Beral,et al.  Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents , 2016, The Lancet.

[19]  Chunyan Wang,et al.  The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis , 2016, Evidence-based complementary and alternative medicine : eCAM.

[20]  Z. Asemi,et al.  Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled trial , 2016, Clinical endocrinology.

[21]  Zheng-Xiao Zhao,et al.  Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. , 2016, Biochemical and biophysical research communications.

[22]  Qifu Li,et al.  Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity , 2016, Scientific Reports.

[23]  T. Sawamura,et al.  Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis. , 2016, Clinical chemistry.

[24]  M. Taghizadeh,et al.  Selenium Supplementation Affects Insulin Resistance and Serum hs-CRP in Patients with Type 2 Diabetes and Coronary Heart Disease , 2016, Hormone and Metabolic Research.

[25]  A. Catapano,et al.  Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. , 2015, Atherosclerosis.

[26]  Junhua Wang,et al.  Renoprotective effects of berberine as adjuvant therapy for hypertensive patients with type 2 diabetes mellitus: Evaluation via biochemical markers and color Doppler ultrasonography. , 2015, Experimental and therapeutic medicine.

[27]  W. Jia,et al.  Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease , 2015, PloS one.

[28]  W. Ni,et al.  Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. , 2015, European journal of pharmacology.

[29]  Xiao Wang,et al.  Berberine Suppresses Adipocyte Differentiation via Decreasing CREB Transcriptional Activity , 2015, PloS one.

[30]  Jun Wang,et al.  Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway , 2015, Journal of Translational Medicine.

[31]  Feiqi Zhu,et al.  Influence of berberine combining with atorvastatin on serum high-sensitivity C-reactive protein and adipocyte fatty acid-binding protein in patients with acute ischemic stroke , 2015 .

[32]  G. Ning,et al.  Berberine activates thermogenesis in white and brown adipose tissue , 2014, Nature Communications.

[33]  Byung-Cheol Lee,et al.  Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. , 2014, Biochimica et biophysica acta.

[34]  B. Liu,et al.  The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment , 2014, Clinical endocrinology.

[35]  W. Willett,et al.  A pooled analysis of waist circumference and mortality in 650,000 adults. , 2014, Mayo Clinic proceedings.

[36]  E. Martínez-Abundis,et al.  Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. , 2013, Metabolic syndrome and related disorders.

[37]  G. De Pergola,et al.  Obesity as a Major Risk Factor for Cancer , 2013, Journal of obesity.

[38]  A. D'Angelo,et al.  Effects of berberine on lipid profile in subjects with low cardiovascular risk , 2013, Expert opinion on biological therapy.

[39]  Shu Meng,et al.  Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention , 2012, Clinical and experimental pharmacology & physiology.

[40]  F. Santilli,et al.  Determinants of increased cardiovascular disease in obesity and metabolic syndrome. , 2011, Current medicinal chemistry.

[41]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[42]  Junling Han,et al.  Modulating gut microbiota as an anti-diabetic mechanism of berberine , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[43]  J. Chen,et al.  Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. , 2010, Talanta.

[44]  G. Davies,et al.  Berberine increases expression of GATA-2 and GATA-3 during inhibition of adipocyte differentiation. , 2009, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[45]  L. Hedges,et al.  Introduction to Meta‐Analysis , 2009, International Coaching Psychology Review.

[46]  G. Ning,et al.  Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. , 2008, The Journal of clinical endocrinology and metabolism.

[47]  Yuebo Zhang,et al.  Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway , 2006 .

[48]  G. Targher,et al.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. , 2005, Diabetes.

[49]  H. Xin,et al.  Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study , 2005, European Journal of Clinical Pharmacology.

[50]  Julian P T Higgins,et al.  Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. , 2017, Epidemiology.

[51]  A. Engin,et al.  The Definition and Prevalence of Obesity and Metabolic Syndrome. , 2017, Advances in experimental medicine and biology.

[52]  P. Clifton,et al.  Effect of weight loss on pulse wave velocity: systematic review and meta-analysis. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[53]  E. Martínez-Abundis,et al.  Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. , 2013, Metabolic syndrome and related disorders.

[54]  Aili Wang,et al.  A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. , 2012, European journal of endocrinology.

[55]  Z. Parveen,et al.  A Review on Therapeutic Applications of Nigella Sativa , 2011 .

[56]  U. Siering,et al.  Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients: Systematic Review and Meta-analysis , 2009 .

[57]  K. Sung,et al.  severity of nonalcoholic fatty liver disease is associated with ncreased cardiovascular risk in a large cohort of non-obese sian subjects i , 2009 .

[58]  S. S. Bahadur,et al.  The berberis story: Berberis vulgaris in therapeutics. , 2007, Pakistan journal of pharmaceutical sciences.